Spectral Medical Inc. provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment activity continues throughout 2024: 93 patients enrolled to-date, Six patients enrolled in the month of February ­ follows the six patients enrolled in January, Twelve patients enrolled in the first two months of 2024 ­ represents the most robust enrollment rates since the start of the Tigris study, With 57 patients to full enrollment, the Company is entering the final push to fully enroll and finish the Tigris trial To support sustained enrollment, Spectral to host an in-person Investigator Meeting March 12th & 13th in conjunction with the 29th International Conference on Advances in Critical Care Nephrology in San Diego Trial Sites: · Currently 21 Tigris trial sites, with continued progress opening an additional four new, high quality clinical sites The Institute for Extracorporeal Life Support (San Antonio, TX) finalized and executed the Tigris clinical trial agreement Expect significant site onboarding activity throughout Q1/24, with final training scheduled at three of the remaining four sites.